BofA Says Buy Teva With Copaxone Patent Loss Out Of The Way
January 31, 2017 at 13:20 PM EST
Shares of Teva Pharmaceutical are sliding after a judge invalidated four patents for its Copaxone drug, an immunosuppressant for the treatment of relapsing-remitting multiple sclerosis.
